Adjusted net income was $0.4 mln, up from a loss in the prior quarter
Company reaffirmed full-year 2026 revenue guidance and expanded Medicaid coverage for core tests
Result Drivers
EXOME AND GENOME VOLUME - Q2 exome and genome test volume grew 32% yr/yr, driving revenue growth
EXPANDED COVERAGE - New Medicaid coverage in Texas and California and Carelon policy expanded access to exome and genome sequencing
PRODUCT UPDATES - Redesigned exome and genome reports launched to streamline delivery of genomic insights to clinicians
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
WGS•
